检索结果-南通市图书馆

Chinese Medical Journal 2012年第23期125卷 4197-4201页

作者： LIU Shan-ying LIANG Ying LIN Tian-xin SU Fang LIANG Wei-wen Uwe Heemann LI Yan Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes Sun Yat-sen Memorial HospitalSun Yat-sen UniversityGuangzhouGuangdong 510120China Department of Endocrinology Sun Yat-sen Memorial HospitalSun Yat-sen UniversityGuangzhouGuangdong 510120China Department of Nephrology Technical University Munich81675 MunichGermany

Background Increased risk of bladder cancer has been reported in diabetic patients. This study was to investigate the roles of mitogen-activated protein kinase kinase （MEK） 1 and 2 in the regulation of human insulin- and insulin glargine-induced proliferation of human bladder cancer T24 cells. Methods In the absence or presence of a selective inhibitor for MEK1 （PD98059） or a specific siRNA for MEK2 （siMEK2）, with or without addition of insulin or glargine, T24 cell proliferation was evaluated by cell counting kit （CCK）-8 assay. Protein expression of MEK2, phosphorylation of ERK1/2 and Akt was analyzed by Western blotting. Results T24 cell proliferation was promoted by PD98059 at 5-20 IJmol/L, inhibited by siMEK2 at 25-100 nmol/L. PD98059 and siMEK2 remarkably reduced phosphorylated ERKI/2. Insulin- and glargine-induced T24 cell proliferation was enhanced by PD98059, suppressed while not blocked by siMEK2. Insulin- and glargine-induced ERKI/2 activation was blocked by PD98059 or siMEK2 treatment, whereas activation of Akt was not affected. Conclusion MEK1 inhibits while MEK2 contributes to normal and human insulin- and insulin glargine-induced human bladder cancer T24 cell proliferation.

关键词： insulin glargine proliferation bladder cancer MEK

Efficacy and Safety of Patient-Led Dosage Adjustments of Insulin glargine: A Preliminary Report of Basal-Supported Oral Therapy for Japanese Type 2 Diabetes Patients

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Journal of Diabetes Mellitus 2014年第2期4卷 77-84页

作者： Shuhei Nakanishi Mitsunobu Kubota Rui Kishimoto Department of Molecular and Internal Medicine Graduate School of Biomedical & Health Sciences Hiroshima University Hiroshima Japan

To evaluate the clinical utility for simple patient administered dose adjustment methods of insulin glargine during outpatient visits compared with a physician managed titration, changes in HbA1c and total daily dose of insulin were evaluated in 23 patients by dividing patients into physician-led (PL) group and self-titration (ST) group who were newly administered glargine basal-supported oral therapy (BOT) while continuing oral antidiabetic drugs at the discretion of their attending physician during regular outpatient visits. In the PL group, one month after initiation of glargine, HbA1c followed a declining trend, although this was not significant (P = 0.07), and decreased significantly after two and three months (P glargine, but did drop markedly after two and three months, with this trend continuing up to 12 months (P < 0.005). On examining the differences between both groups, we found that the initial dose was significantly larger in the PL group (P < 0.05), whereas the dose increased significantly more in the ST group after three months. While the insulin dose after 12 months was large in the ST group, no statistically significant difference was noted between the two groups (P = 0.14) whereas HbA1c was significantly low in the ST group. In conclusion, we believe that patient-led basal insulin dosage adjustment is an effective and useful therapeutic option when they can master self-monitoring of blood glucose.

关键词： glargine Self-Titration BOT T2DM Insulin

Starting glargine in insulin-nave type 2 diabetic patients based on body mass index is safe

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Diabetes 2014年第1期5卷 69-75页

作者： Denise R Franco Juliana Baptista Fatima RM Abreu Risoneide B Batista Freddy G Eliaschewitz Medical Department Clinical Research Center (CPCLIN) Associa o do Diabetes Brazil (ADJ) Hospital Israelita Albert Einstein

AIM:To evaluate the safety of four insulin titration algorithms in a homogeneous population of insulin-na ve type 2 diabetic patients.METHODS:We conducted a 24-wk,open,single-center study with 92 insulin-na ve type 2 diabetes patients who failed treatment with one or two oral drugs.The patients were randomized to one of the four following algorithms:LANMET(n=26)and LANMET PLUS(n=22)algorithms,whose patients received a fixed initial insulin dose of 10 U,and DeGold(n=23)and DeGold PLUS(n=21)algorithms,whose patients’initial insulin dose was based on their body mass index(BMI).In addition,patients in the PLUS groups had their insulin titrated twice a week from 2 to 8 U.In the other two groups,the titration was also performed also twice a week,but in a fixed increments of 2 U.The target fasting glucose levels for both groups was 100 mg/dL.RESULTS:There was no significant difference in efficacy parameters.There was no significant difference when comparing moderate hypoglycemia events in algorithms starting with a 10 U fixed dose and algorithms based on BMI.However,there was a significant increase in moderate hypoglycemia events among the PLUS treated patients when the LANMET and DeGold algorithms were compared with the 2 fast-titration PLUS algorithms.We observed 12 hypoglycemia events in the first group,which corresponded to 0.94 events/patient per year,and we observed 42 events in the second group,which corresponded to 2.81 events/patient per year(Pglargine based on BMI is safe,but fast titration algorithms increase the risk of moderate hypoglycemia.

关键词： Type 2 diabetes Insulin glargine Basal in-sulin Hypoglycemia Titration algorithms

Assessing insulin effectiveness at the end of the day: Once-daily versus twice-daily insulin glargine injection

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Diabetes Mellitus 2012年第2期2卷 203-207页

作者： Mark R. Burge Eric R. Schroeder Stephen Mitchell Department of Medicine Endocrinology The Vancouver Clinic Vancouver USA Division of Cardiovascular Medicine South Miami Hospital Miami USA University of New Mexico Health Sciences Center Department of Medicine Division of Endocrinology and Metabolism Albuquerque USA

Objective: Evidence supporting the twice-daily administration of insulin glargine as an approach to address its waning effectiveness at the end of a 24 hour period is sparse. We hypothesized that insulin concentrations determined during the last four hours of a 24 hour period would be greater when identical doses of insulin glargine were administered twice-daily as compared to once-daily among type 1 diabetes patients. Research Methods: Ten subjects with insulin deficient type 1 diabetes were admitted for two 38-hour studies at least one week apart. Patients received full-dose insulin glargine once daily at 0800 and half-dose insulin glargine twice-daily at 0800 and 2000 for at least one week in random order prior to overnight studies. Overnight glucose was stabilized with intravenous insulin on the evening prior to study, and subjects fasted and did not receive short acting insulin during the study period. Insulin concentrations were assessed every 30 minutes with an ultrasensitive assay between study hours 20 and 24. Results: Insulin concentrations for the final four hours of study period did not differ between once-daily and twice-daily insulin glargine administration (p = 0.38). Home glucose testing results and overnight plasma glucose concentrations did not differ between study conditions. Conclusions: These results demonstrate that insulin concentrations are equivalent during the last four hours of a 24-hour period when insulin glargine is administered once- or twice-daily. These findings do not support a role for twice-daily insulin glargine in the management of patients with type 1 diabetes.

关键词： Insulin Injection Timing Insulin glargine Basal Insulin Type 1 Diabetes

Compared with insulin glargine, insulin degludec narrows the day-to-day variability in the glucose-lowering effect rather than lowering blood glucose levels

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Diabetes Mellitus 2013年第4期3卷 244-251页

作者： Susumu Ogawa Kazuhiro Nako Masashi Okamura Miho Senda Takuya Sakamoto Sadayoshi Ito Division of Nephrology Endocrinology and Vascular Medicine Tohoku University Hospital Sendai Japan

Background: Changes in the day-to-day variability in the glucose-lowering effect of insulin [fluctuations of blood glucose levels (BG) seen during the same time period] that occur when insulin glargine (glargine) is replaced with insulin degludec (degludec) have not been sufficiently evaluated. Subjects: Five diabetics with unstable BG undergoing basal-bolus treatment using insulin glargine as basal insulin. Methods: Basal insulin was changed from glargine to same-dose degludec. The subjects’ HbA1c, glycoalbumin, and 1.5-anhydro-D-glucitol were measured before and after the switchover. Fasting blood glucose concentration (FBG) and predinner blood glucose concentration (PDBG) were measured continuously for 28 days immediately before the switchover, and 28 days immediately thereafter, to compare and evaluate 1) the changes in their mean values and standard deviations (SDs) before and after the switchover, and 2) the frequency of appearance of BG of over 180 mg/dL (BG ≥ 180) and under 70 mg/dL (BG Results: The levels of HbA1c, glycoalbumin, FBG’s mean value, SDs, BG ≥ 180 and BG Conclusion: The possibility was shown that degludec, to a greater extent than glargine, suppressed daily fluctuations of FBG and PDBG, suppressed the occurrence frequency of hyperglycemia and hypoglycemia, and exerted more steady hypoglycemic actions.

关键词： Degludec glargine Hyperglycemia Hypoglycemia The Day-to-Day Variability in the Glucose-Lowering Effect of Insulin

From insulin detemir to glargine: Effect on glycemic control and psychological wellbeing in patients with diabetes mellitus type 2 in daily practice

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Diabetes Mellitus 2012年第1期2卷 101-108页

作者： Thiemo F. Veneman Fred E. M. G. Storms Ingo A. Eland Paul K. P. Bouter Department of Internal Medicine Ziekenhuisgroep Twente Almelo Netherlands

The success of a specific treatment is traditionally judged according to parameters such as HbA1c. However, other, patient-reported outcomes (PRO) of (insulin) therapy, become increasingly more important. The introduction of (basal) insulin-analogues could possibly improve PRO, particularly “quality of life”. Direct comparative studies between once daily insulin glargine and once to twice or twice daily insulin detemir have previously shown differences in insulin dosage, dosing frequency and weight gain. Whether this leads to a difference in quality of life in patients who are transferred from insulin detemir to insulin glargine remains to be determined. To establish the effect of insulin glargine on quality of life and patient satisfaction in patients with DM2 who are in poor metabolic control with a (human) basal insulin, a large prospective, observational study in Dutch daily practice was performed. The results of the patient population switched from NPH-insulin to insulin glargine have been published previously. In this article the results of the group of patients treated with insulin detemir before the observation period are described. The results of this observational study show that changing basal insulin therapy to insulin glargine in patients with DM2 who are in poor glycemic control with insulin detemir leads to a clinically significant improvement of glycemic control as well as emotional wellbeing, despite a small increase in weight. Whether other factors such as decreased dosing frequency play a role remains to be determined by future studies.

关键词： Insulin glargine Insulin Detemir Psychological Wellbeing Metabolic Control Type 2 Diabetes

Iowa medicaid 2: lapse of glycemic control on abrupt transition from insulin glargine to insulin detemir in type 2 diabetes mellitus

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Diabetes Mellitus 2011年第4期1卷 124-128页

作者： Udaya Kabadi Department of Medicine University of Iowa

Background: Iowa Care (Iowa Medicaid in State of Iowa, USA), switched insulin glargine to detemir in subjects with Diabetes Mellitus (DM) without the knowledge or approval of healthcare providers beginning 8/2006.Impact of this transition in subjects with Type 1 DM is recently reported. Objective: To examine the impact of this transition on various parameters of diabetes management in Type 2 DM. Subjects and Methods: A retrospective review of the records of subjects with Type 2 DM was conducted until 8/2007 in whom the transition had occurred. Only those subjects with adequate glycemic control while receiving insulin glargine [GI] and completing at least 3 months of therapy with insulin detemir [DI] are included in this report. Ten subjects with Type 2 DM, duration 7 ± 2 years with age, 55 ± 3 years who were switched from GI to DI (Group 1) fulfilled the criteria for inclusion. Subjects were switched from GI in Q AM to DI Q HS in the same daily dose. Glycemic control (HbA1c), body weight, daily insulin dose (Units) and severe hypoglycemic events during the last 2 weeks of the period, pre switch and again at the end of 3 months post switch were assessed. Records of 8 subjects matched for age, duration of DM, glycemic control while receiving GI for additional 3 months (Group 2) during the same period were examined for comparison. All subjects were followed in the outpatient clinic at intervals of 3 months. Results Glycemic control remained stable on continuing GI AM;HbA1c;7.1 ± 0.3 to 7.1 ± 0.3%, while it worsened on switching to DI Q HS;HbA1c, 7.1 ± 0.3 to 8.1 ± 0.5 [P glargine to insulin detemir in subjects with Type 2 DM is likely to result in lapse of glycemic control which may cause decreased quality of life. Furthermore, use of insulin detemir may result in increased costs due to need of the higher daily dose as well as additiona

关键词： Type 2 Diabetes Insulin glargine Insulin Detemir Glycemic Control

Effect of Insulin glargine on Cardiovascular Risk Analysed by Mean HRV

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Health 2019年第1期11卷 20-24页

作者： Marchitto Nicola Marcinnò Mariaconcetta Petrucci Alessia Apicella Giovanni Dal Maso Serenella Gioia Raimondi Gianfranco Internal Medicine Department Alfredo Fiorini Hospital Terracina Italy Nursing Department Sapienza University of Rome Rome Italy Department of Medico-Surgical Sciences and Biotechnologies Sapienza University of Rome Rome Italy

Type 2 diabetes mellitus is an insidious disease that is increasingly present in geriatric population [1]. The greatest difficulty is represented by glycaemic control in geriatric patients often not very compliant with diet therapy and drug therapy. A new insulin glargine 300 units/ml formulation seems improve patient compliance due to the lower volume of insulin to be injected and improved glycaemic control over 24 hours. The HRV signal, derived from digital electrocardiographic recording, is the simplest and most immediate analysis that consists in calculating some temporal parameters [2]. HRV is a simple statistics derived from beat-beat intervals of sinus origin expressed as units of time in milliseconds. Data in the literature indicate that a decrease in HRV, measured with time domain analysis, denotes a worse prognosis and/or an increased risk of mortality in patients with heart disease, especially in the elderly ones.

关键词： Insulin glargine Diabetes HRV Cardiovascular Risk Geriatry

Assessment of Safety and Effectiveness of Glaritus<sup>®</sup>(Wockhardt’s Insulin glargine) in a Prospective, Multi-Centric Post Marketing Observational Study in Nepalese Having Type 2 Diabetes Mellitus

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Open Journal of Endocrine and Metabolic Diseases 2019年第2期9卷 21-33页

作者： Ansumali Joshi Bhojraj Adhikari Basant Tamrakar Gaurav Puppalwar Agam Shah Rishi Jain Kathmandu Diabetes & Thyroid Centre Pvt. Ltd. Kathmandu Nepal Pushpanjali Hospital Bharatpur Nepal Fishtail Hospital & Research Centre Pvt. Ltd. Pokhara Nepal Medical Affairs Wockhardt Ltd. Mumbai India

Background: Nepal is one of the fastest urbanizing countries in South Asia and is facing the consequences of urban lifestyle leading to obesity and metabolic syndrome. Type 2 diabetes mellitus (T2DM) is currently a high-burden disease in Nepal with a prevalence of 8.4%. Of these 8% - 18% patients are on insulin and 42% patients were reported to have uncontrolled diabetes in the past year. This suggests a need for better therapy options in terms of efficacy and safety. The current study was designed to investigate the effects of Insulin glargine-based therapy in Nepalese with T2DM who could not achieve adequate glycemic control with oral and non-glargine-insulin therapy. Methods: This is a prospective, multi-centric, single arm and post marketing observational study to assess the safety and effectiveness of Glaritus®(Wockhardt’s Insulin glargine) in 52 T2DM patients from 3 (three) different study sites in Nepal (Bharatpur, Kathmandu and Pokhra) from September 2015 to December 2016. The primary objective of the study was to evaluate the safety of Glaritus®, mainly in terms of hypoglycemia, renal function tests and liver function tests. The secondary objectives were to evaluate the effectiveness of Glaritus®in terms of percentage of patients achieving HbA1c goal of less than 7%, mean changes in HbA1c & fasting plasma glucose (FPG) levels from baseline till the end of study. Results: 3.85% of subjects experienced hypoglycemia during first 3 months of therapy whereas 1.92% had similar experience in next 3 months of therapy. The mean HbA1c values reduced from 9.16% to 7.15% at the end of study. 21.05% of the enrolled subjects achieved the goal of HbA1c ®was well tolerated by the study patients. Conclusion: In patients with type 2 diabetes mellitus inadequately controlled on oral hypoglycemic agents and/or insulin, initiation with Glaritus®significantly improved glycemic control with good tolerability and acceptability. This analysis in T2DM Nepalese patients shows that by significantly improving gly

关键词： Insulin glargine Type 2 Diabetes Nepalese Patients Hypoglycemia Basal Insulin HbA1c Fasting Plasma Glucose Post Marketing Surveillance

Simple Insulin Dose Adjustment Using 3-3-1 Algorithm in Japanese Patients with Type 2 Diabetes: Start Kanazawa Study (Self-Titration Aggressive Algorithm with glargine Trial)

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Diabetes Mellitus 2016年第3期6卷 197-203页

作者： Kenji D. Furukawa Naoto Yamaaki Aya Fujimoto Kiminori Ohyama Hiroaki Muramoto Department of Internal Medicine Japan Community Health care Organization (JCHO) Kanazawa Hospital Kanazawa Japan

We implemented a 3-3-1 algorithm in order to provide safe and simple self-titration in patients who newly initiated BOT as well as who were already on BOT and evaluated its utility in clinical setting. A total of 46 patients, 21 patients in the newly-initiated group and 25 patients in the existing BOT group performed dose adjustment using 3-3-1 algorithm. HbA1c was significantly improved 4 weeks after the initiation from 8.5% ± 1.2% at baseline to 7.3% ± 0.7% at the final evaluation (p 0.01, vs. Baseline). The average daily insulin units increased throughout the study period from 10.1 ± 6.7 at baseline to 14.6 ± 8.9 units at the final evaluation. Weight didn’t significantly change throughout the study (p = 0.12). The incidents of hypoglycemia were 0.8/month during the insulin dose self-adjustment period and 0.4/month during the follow-up period. The 3-3-1 algorithm using insulin glargine provided a safe and simple dose adjustment and demonstrated its utility in patients who were newly introduced to insulin treatment as well as who were already on BOT.

关键词： glargine Self-Titration BOT T2DM Insulin 3-3-1 Algorithm